PL2829283T3 - Sposoby leczenia nowotworu z zastosowaniem immunotoksyny - Google Patents

Sposoby leczenia nowotworu z zastosowaniem immunotoksyny

Info

Publication number
PL2829283T3
PL2829283T3 PL14172801T PL14172801T PL2829283T3 PL 2829283 T3 PL2829283 T3 PL 2829283T3 PL 14172801 T PL14172801 T PL 14172801T PL 14172801 T PL14172801 T PL 14172801T PL 2829283 T3 PL2829283 T3 PL 2829283T3
Authority
PL
Poland
Prior art keywords
immunotoxin
methods
treating cancer
cancer
treating
Prior art date
Application number
PL14172801T
Other languages
English (en)
Inventor
Uwe Zangenmeister-Wottke
Paolo Claudio Di
Dominique Christine Tschudi
Nicholas Ronald Glover
Dimitri Peter Fitsialos
Original Assignee
Universität Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Zürich filed Critical Universität Zürich
Publication of PL2829283T3 publication Critical patent/PL2829283T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL14172801T 2003-04-30 2004-04-30 Sposoby leczenia nowotworu z zastosowaniem immunotoksyny PL2829283T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46660803P 2003-04-30 2003-04-30
EP14172801.4A EP2829283B1 (en) 2003-04-30 2004-04-30 Methods for treating cancer using an immunotoxin
EP04730425A EP1635868A1 (en) 2003-04-30 2004-04-30 Methods for treating cancer using an immunotoxin
EP10011667.2A EP2382990B1 (en) 2003-04-30 2004-04-30 Methods for treating cancer using an immunotoxin

Publications (1)

Publication Number Publication Date
PL2829283T3 true PL2829283T3 (pl) 2017-12-29

Family

ID=33418401

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10011667T PL2382990T3 (pl) 2003-04-30 2004-04-30 Sposoby leczenia raka z zastosowaniem immunotoksyny
PL14172801T PL2829283T3 (pl) 2003-04-30 2004-04-30 Sposoby leczenia nowotworu z zastosowaniem immunotoksyny

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10011667T PL2382990T3 (pl) 2003-04-30 2004-04-30 Sposoby leczenia raka z zastosowaniem immunotoksyny

Country Status (13)

Country Link
US (6) US20070196366A1 (pl)
EP (3) EP2829283B1 (pl)
JP (1) JP4988333B2 (pl)
CN (1) CN100417414C (pl)
AU (1) AU2004234191A1 (pl)
CA (2) CA2524124C (pl)
DK (2) DK2829283T3 (pl)
ES (2) ES2526219T3 (pl)
HU (1) HUE033533T2 (pl)
IL (2) IL171643A (pl)
PL (2) PL2382990T3 (pl)
PT (2) PT2382990E (pl)
WO (1) WO2004096271A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039354D1 (de) * 1999-04-09 2008-08-14 Univ Zuerich Verfahren zur Stabilisierung von chimären Immunoglobulinen oder Immunoglobulinfragmenten und stabilisiertes Anti-EGP-2-scFv-Fragment
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
DK2829283T3 (en) 2003-04-30 2017-09-18 Univ Zuerich METHOD OF TREATING CANCER USING IMMUNOTOXIN
US20060127399A1 (en) * 2004-09-13 2006-06-15 Defu Zeng Compositions and methods for inducing chimerism in a subject
CA2593648A1 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
JP5014157B2 (ja) * 2005-02-16 2012-08-29 ユニバーシティー オブ チューリッヒ 改良免疫毒素を用いた癌治療法
EP2004695A2 (en) 2005-07-08 2008-12-24 Xencor, Inc. Optimized anti-ep-cam antibodies
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
WO2007071061A1 (en) * 2005-12-23 2007-06-28 Viventia Biotech Inc. Methods for generating and screening fusion protein libraries and uses thereof
WO2008128330A1 (en) 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
RU2350338C2 (ru) * 2007-05-14 2009-03-27 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения поверхностного рака мочевого пузыря
RU2352340C1 (ru) * 2007-06-27 2009-04-20 Федеральное Государственное Учреждение Ростовский научно-исследовательский онкологический институт Росмедтехнологий Способ химиотерапии при раке мочевого пузыря
CA2700815A1 (en) * 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
US8110193B2 (en) * 2007-12-21 2012-02-07 City Of Hope Methods for conditioning a subject for hematopoietic cell transplantation
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
US20100055107A1 (en) * 2008-07-31 2010-03-04 Defu Zeng Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning
US20120034223A1 (en) * 2008-11-06 2012-02-09 Hall Christopher J Methods of improving the therapeutic efficacy and utility of antibody fragments
AU2009322126B2 (en) * 2008-12-05 2013-06-20 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
EP3385279B1 (en) 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2011031441A1 (en) * 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
JP6048660B2 (ja) 2009-09-21 2016-12-21 ランジュ ラルハン 甲状腺癌を診断および処置するための方法および組成物
WO2011038142A2 (en) * 2009-09-24 2011-03-31 The Regents Of The University Of California Bladder cancer specific ligand peptides
US9321820B2 (en) * 2009-10-14 2016-04-26 The Regents Of The University Of Colorado Compositions and methods for treating bladder cancer
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
EP2567235B1 (en) 2010-05-04 2017-08-30 Paul Walfish Method for the diagnosis of epithelial cancers by the detection of epicd polypeptide
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
CN105188762A (zh) * 2013-04-12 2015-12-23 维文蒂阿生物公司 用于肝细胞癌检测和治疗的组合物和方法
BR112016007232A2 (en) 2013-10-02 2018-01-23 Viventia Bio Inc. anti-epcam antibodies and methods of use
JP6847846B2 (ja) * 2015-03-12 2021-03-24 セセン バイオ，インコーポレイテッド Ｅｐｃａｍ陽性膀胱癌を標的とする投薬戦略
AU2016228755B2 (en) * 2015-03-12 2020-09-10 Viventia Bio Inc. Methods of treatment for EPCAM positive bladder cancer
WO2018174053A1 (ja) * 2017-03-22 2018-09-27 学校法人兵庫医科大学 標準化学療法に不応又は不耐で治癒切除不能な進行又は再発癌患者の治療のための医薬
WO2018220467A1 (en) * 2017-05-30 2018-12-06 Foroogh Nejatollahi Anti-muc18 human immunotoxin and applications thereof
US11965004B2 (en) 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof
CN118240025A (zh) 2017-07-10 2024-06-25 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
CN108122613B (zh) * 2018-01-15 2022-04-01 北京颐圣智能科技有限公司 基于健康预测模型的健康预测方法和装置
CN110194803B (zh) * 2019-06-26 2021-01-05 上海科棋药业科技有限公司 一种靶向EpCAM的嵌合抗原受体及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4677070A (en) 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5082927A (en) 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4933288A (en) 1986-11-21 1990-06-12 Cetus Corporation Use of a modified soluble Pseudomonas exotoxin A in immunoconjugates
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5621078A (en) 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
CA2072891C (en) 1990-01-02 1999-12-21 Ira Pastan Pseudomonas exotoxin fusion proteins having carboxyl alterations with increased cytotoxicity
US5458878A (en) 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
EP0531434B1 (en) 1990-05-11 1999-07-14 THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
AU675440B2 (en) 1992-06-18 1997-02-06 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant (pseudomonas) exotoxin with increased activity
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
ATE247488T1 (de) 1995-10-13 2003-09-15 Us Gov Health & Human Serv Immunotoxin enthaltend ein disulfid- stabilisiertes antikörperfragment
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
WO1997045538A1 (en) 1996-05-31 1997-12-04 Medigene Ag Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
JP2001504334A (ja) 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
CA2295189C (en) 1997-06-06 2010-11-23 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
PT1037927E (pt) * 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1137941B2 (en) 1998-12-10 2013-09-11 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
DE60039354D1 (de) 1999-04-09 2008-08-14 Univ Zuerich Verfahren zur Stabilisierung von chimären Immunoglobulinen oder Immunoglobulinfragmenten und stabilisiertes Anti-EGP-2-scFv-Fragment
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
US20030148950A1 (en) 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
IL161418A0 (en) * 2001-10-15 2004-09-27 Immunomedics Inc Direct targeting binding proteins
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
SI21272A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli
CA2424255A1 (en) 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
DK2829283T3 (en) 2003-04-30 2017-09-18 Univ Zuerich METHOD OF TREATING CANCER USING IMMUNOTOXIN
PL1737961T3 (pl) 2004-03-19 2013-12-31 Merck Patent Gmbh Zmodyfikowane białka bouganiny, cytotoksyny i sposoby oraz ich zastosowania
NZ552476A (en) 2004-06-10 2009-09-25 Viventia Biotech Inc Tumor specific antibody
US20090171317A1 (en) 2006-03-10 2009-07-02 Ebrahim Versi Self-Catheterization Device To Administes Compounds To The Bladder
EP2079840A4 (en) 2006-10-30 2010-06-30 Viventia Biotech Inc IMMUNOTOXIN FUSIONS COMPRISING PROTEASEPLATABLE LINKER-ASSOCIATED ANTIBODY FRAGMENT AND PLANT TOXIN
WO2008128330A1 (en) 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
CA2700815A1 (en) 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
CA2756246A1 (en) 2009-04-08 2010-10-14 Heinz Faulstich Amatoxin-armed target-binding moieties for the treatment of cancer
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CN107080847A (zh) 2011-06-24 2017-08-22 森彻斯有限公司 细胞外靶向药物缀合物
CN105188762A (zh) 2013-04-12 2015-12-23 维文蒂阿生物公司 用于肝细胞癌检测和治疗的组合物和方法
BR112016007232A2 (en) 2013-10-02 2018-01-23 Viventia Bio Inc. anti-epcam antibodies and methods of use
JP6847846B2 (ja) 2015-03-12 2021-03-24 セセン バイオ，インコーポレイテッド Ｅｐｃａｍ陽性膀胱癌を標的とする投薬戦略
WO2017040801A2 (en) 2015-09-02 2017-03-09 Viventia Bio Inc. Methods for making and using an immunoconjugate for the treatment of cancer

Also Published As

Publication number Publication date
CA2524124C (en) 2014-03-25
JP2006526576A (ja) 2006-11-24
CA2524124A1 (en) 2004-11-11
EP2829283B1 (en) 2017-06-07
US9259484B2 (en) 2016-02-16
US20160199507A1 (en) 2016-07-14
HUE033533T2 (en) 2017-12-28
US20140178417A1 (en) 2014-06-26
WO2004096271A1 (en) 2004-11-11
PT2382990E (pt) 2014-12-29
CN100417414C (zh) 2008-09-10
IL213621A (en) 2013-12-31
US20210317203A1 (en) 2021-10-14
IL213621A0 (en) 2011-07-31
DK2382990T3 (en) 2014-12-15
US10858429B2 (en) 2020-12-08
EP2829283A1 (en) 2015-01-28
US20100249039A1 (en) 2010-09-30
US20070196366A1 (en) 2007-08-23
PL2382990T3 (pl) 2015-04-30
PT2829283T (pt) 2017-09-08
EP2382990B1 (en) 2014-09-17
IL171643A (en) 2011-08-31
CA2826735A1 (en) 2004-11-11
CN1816352A (zh) 2006-08-09
HK1206617A1 (en) 2016-01-15
EP1635868A1 (en) 2006-03-22
DK2829283T3 (en) 2017-09-18
CA2826735C (en) 2019-06-04
ES2526219T3 (es) 2015-01-08
US11713351B2 (en) 2023-08-01
EP2382990A1 (en) 2011-11-02
US20210040203A1 (en) 2021-02-11
JP4988333B2 (ja) 2012-08-01
AU2004234191A1 (en) 2004-11-11
US11713352B2 (en) 2023-08-01
ES2639301T3 (es) 2017-10-26
US8545840B2 (en) 2013-10-01

Similar Documents

Publication Publication Date Title
IL213621A0 (en) Methods for treating cancer using an immunotoxin
EP2671581B8 (en) Compositions and methods for treating cancer
SG133592A1 (en) Methods for treating prostate cancer with herbal compositions
ZA200508427B (en) Methods for treating interleuking-6 related diseases
ZA200705059B (en) Cancer treatment method
SI1803718T1 (sl) 4-tetrazolil-4-fenilpiperidinski derivati za zdravljenje bolečine
IL176919A0 (en) Methods and compositions for treating cancer
EP1755394A4 (en) METHOD OF TREATING CANCER
PT1830847E (pt) Tratamento para o cancro
EP1909854A4 (en) METHOD FOR TREATING CANCER
PL379264A1 (pl) Kompozycje i sposoby leczenia raka przy zastosowaniu IGSF9 i LIV-1
GB0428187D0 (en) Cancer treatment
IL179323A0 (en) Cancer treatment method
GB0413346D0 (en) Treating cancer
IL179359A0 (en) Cancer treatment method
EP1802617A4 (en) CANCER TREATMENT METHOD
GB0223325D0 (en) Treating cancer
HK1087646A (en) Methods for treating cancer using an immunotoxin
GB0404675D0 (en) Cancer treatment
GB2383538B (en) Cancer treatment
GB0327499D0 (en) Cancer treatment
GB0329081D0 (en) Radiotherapy apparatus
GB0324482D0 (en) Methods for the treatment of cancer
HK1087129A (en) Peptabody for cancer treatment
GB0216634D0 (en) Treating cancer